| Product Code: ETC12629557 | Publication Date: Apr 2025 | Updated Date: Nov 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | No. of Pages: 65 | No. of Figures: 34 | No. of Tables: 19 | |
The market for large molecules drug substance CDMO import shipments in Latvia saw significant growth with a high HHI concentration in 2024. Top exporting countries, including Metropolitan France, Germany, Lithuania, Poland, and the USA, played crucial roles in driving this growth. Despite a remarkable CAGR of 43.42% from 2020 to 2024, the market experienced a notable decline in growth rate from 2023 to 2024 at -57.01%. This indicates a dynamic and rapidly evolving landscape for large molecules drug substance imports in Latvia, reflecting the influence of key exporting nations and market fluctuations.

1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Latvia Large Molecules Drug Substance CDMO Market Overview |
3.1 Latvia Country Macro Economic Indicators |
3.2 Latvia Large Molecules Drug Substance CDMO Market Revenues & Volume, 2021 & 2031F |
3.3 Latvia Large Molecules Drug Substance CDMO Market - Industry Life Cycle |
3.4 Latvia Large Molecules Drug Substance CDMO Market - Porter's Five Forces |
3.5 Latvia Large Molecules Drug Substance CDMO Market Revenues & Volume Share, By Service Type, 2021 & 2031F |
3.6 Latvia Large Molecules Drug Substance CDMO Market Revenues & Volume Share, By Molecule Type, 2021 & 2031F |
3.7 Latvia Large Molecules Drug Substance CDMO Market Revenues & Volume Share, By Stage, 2021 & 2031F |
3.8 Latvia Large Molecules Drug Substance CDMO Market Revenues & Volume Share, By Application, 2021 & 2031F |
3.9 Latvia Large Molecules Drug Substance CDMO Market Revenues & Volume Share, By End User, 2021 & 2031F |
4 Latvia Large Molecules Drug Substance CDMO Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing demand for biologics and large molecule drugs globally |
4.2.2 Growing trend of outsourcing drug substance manufacturing to CDMOs for cost-efficiency and expertise |
4.2.3 Government initiatives to promote the life sciences industry in Latvia |
4.3 Market Restraints |
4.3.1 Stringent regulatory requirements and quality standards for large molecule drug manufacturing |
4.3.2 Competition from established CDMOs in other regions |
4.3.3 Limited availability of skilled workforce in the biopharmaceutical industry in Latvia |
5 Latvia Large Molecules Drug Substance CDMO Market Trends |
6 Latvia Large Molecules Drug Substance CDMO Market, By Types |
6.1 Latvia Large Molecules Drug Substance CDMO Market, By Service Type |
6.1.1 Overview and Analysis |
6.1.2 Latvia Large Molecules Drug Substance CDMO Market Revenues & Volume, By Service Type, 2021 - 2031F |
6.1.3 Latvia Large Molecules Drug Substance CDMO Market Revenues & Volume, By Process Development, 2021 - 2031F |
6.1.4 Latvia Large Molecules Drug Substance CDMO Market Revenues & Volume, By Manufacturing, 2021 - 2031F |
6.1.5 Latvia Large Molecules Drug Substance CDMO Market Revenues & Volume, By Analytical Services, 2021 - 2031F |
6.1.6 Latvia Large Molecules Drug Substance CDMO Market Revenues & Volume, By Regulatory Support, 2021 - 2031F |
6.1.7 Latvia Large Molecules Drug Substance CDMO Market Revenues & Volume, By Packaging, 2021 - 2031F |
6.2 Latvia Large Molecules Drug Substance CDMO Market, By Molecule Type |
6.2.1 Overview and Analysis |
6.2.2 Latvia Large Molecules Drug Substance CDMO Market Revenues & Volume, By Monoclonal Antibodies, 2021 - 2031F |
6.2.3 Latvia Large Molecules Drug Substance CDMO Market Revenues & Volume, By Recombinant Proteins, 2021 - 2031F |
6.2.4 Latvia Large Molecules Drug Substance CDMO Market Revenues & Volume, By Peptides, 2021 - 2031F |
6.2.5 Latvia Large Molecules Drug Substance CDMO Market Revenues & Volume, By Nucleic Acids, 2021 - 2031F |
6.2.6 Latvia Large Molecules Drug Substance CDMO Market Revenues & Volume, By Viral Vectors, 2021 - 2031F |
6.3 Latvia Large Molecules Drug Substance CDMO Market, By Stage |
6.3.1 Overview and Analysis |
6.3.2 Latvia Large Molecules Drug Substance CDMO Market Revenues & Volume, By Preclinical, 2021 - 2031F |
6.3.3 Latvia Large Molecules Drug Substance CDMO Market Revenues & Volume, By Clinical, 2021 - 2031F |
6.3.4 Latvia Large Molecules Drug Substance CDMO Market Revenues & Volume, By Commercial, 2021 - 2031F |
6.3.5 Latvia Large Molecules Drug Substance CDMO Market Revenues & Volume, By Late-Stage, 2021 - 2031F |
6.3.6 Latvia Large Molecules Drug Substance CDMO Market Revenues & Volume, By Early-Stage, 2021 - 2031F |
6.4 Latvia Large Molecules Drug Substance CDMO Market, By Application |
6.4.1 Overview and Analysis |
6.4.2 Latvia Large Molecules Drug Substance CDMO Market Revenues & Volume, By Oncology, 2021 - 2031F |
6.4.3 Latvia Large Molecules Drug Substance CDMO Market Revenues & Volume, By Immunology, 2021 - 2031F |
6.4.4 Latvia Large Molecules Drug Substance CDMO Market Revenues & Volume, By Neurology, 2021 - 2031F |
6.4.5 Latvia Large Molecules Drug Substance CDMO Market Revenues & Volume, By Rare Diseases, 2021 - 2031F |
6.4.6 Latvia Large Molecules Drug Substance CDMO Market Revenues & Volume, By Infectious Diseases, 2021 - 2031F |
6.5 Latvia Large Molecules Drug Substance CDMO Market, By End User |
6.5.1 Overview and Analysis |
6.5.2 Latvia Large Molecules Drug Substance CDMO Market Revenues & Volume, By Pharmaceutical Companies, 2021 - 2031F |
6.5.3 Latvia Large Molecules Drug Substance CDMO Market Revenues & Volume, By Biopharmaceutical Companies, 2021 - 2031F |
6.5.4 Latvia Large Molecules Drug Substance CDMO Market Revenues & Volume, By Research Institutes, 2021 - 2031F |
6.5.5 Latvia Large Molecules Drug Substance CDMO Market Revenues & Volume, By CROs, 2021 - 2031F |
6.5.6 Latvia Large Molecules Drug Substance CDMO Market Revenues & Volume, By CMOs, 2021 - 2031F |
7 Latvia Large Molecules Drug Substance CDMO Market Import-Export Trade Statistics |
7.1 Latvia Large Molecules Drug Substance CDMO Market Export to Major Countries |
7.2 Latvia Large Molecules Drug Substance CDMO Market Imports from Major Countries |
8 Latvia Large Molecules Drug Substance CDMO Market Key Performance Indicators |
8.1 Percentage of revenue from new biologic drug projects |
8.2 Number of strategic partnerships with biopharmaceutical companies |
8.3 Percentage of capacity utilization in manufacturing facilities |
8.4 Time to market for new large molecule drug substances |
8.5 Number of patents filed for innovative manufacturing processes |
9 Latvia Large Molecules Drug Substance CDMO Market - Opportunity Assessment |
9.1 Latvia Large Molecules Drug Substance CDMO Market Opportunity Assessment, By Service Type, 2021 & 2031F |
9.2 Latvia Large Molecules Drug Substance CDMO Market Opportunity Assessment, By Molecule Type, 2021 & 2031F |
9.3 Latvia Large Molecules Drug Substance CDMO Market Opportunity Assessment, By Stage, 2021 & 2031F |
9.4 Latvia Large Molecules Drug Substance CDMO Market Opportunity Assessment, By Application, 2021 & 2031F |
9.5 Latvia Large Molecules Drug Substance CDMO Market Opportunity Assessment, By End User, 2021 & 2031F |
10 Latvia Large Molecules Drug Substance CDMO Market - Competitive Landscape |
10.1 Latvia Large Molecules Drug Substance CDMO Market Revenue Share, By Companies, 2024 |
10.2 Latvia Large Molecules Drug Substance CDMO Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here